Aktis Oncology Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing a proprietary radiopharmaceutical platform with two lead clinical programs targeting Nectin-4 and B7-H3, both showing promising early data and broad multi-indication potential. Robust supply chain and manufacturing infrastructure support aggressive clinical expansion, with key data readouts and new candidates expected in 2027 and early next year.
-
AKY-2519, a B7-H3-targeting radiopharmaceutical, demonstrated robust tumor uptake, high tumor-to-normal tissue dose ratios, and favorable safety in early studies. Experts highlighted its potential to address unmet needs in prostate and other solid tumors, with clinical trials underway in multiple indications.
-
The company is advancing miniprotein radioconjugate therapies targeting Nectin-4 and B7-H3, supported by a robust discovery platform and strong financial position. Key clinical updates are expected in 2027, with ongoing collaborations and manufacturing investments to accelerate development and patient access.
-
AKY-2519, a B7-H3-targeted radioconjugate, has entered phase I-B trials for mCRPC, with a parallel basket trial in other solid tumors planned for late 2026. Imaging and dosimetry data will be presented at ASCO, and preliminary clinical data are expected in 2027.
-
The company is advancing a novel radiopharmaceutical platform with lead programs targeting Nectin-4 and B7-H3, both showing promising early clinical and imaging data. Robust supply chain, strong financials, and strategic partnerships position it for broad impact and sustained growth.
-
Radiopharmaceuticals are poised for major growth, with new miniprotein binder technology enabling first-in-class therapies targeting Nectin-4 and B7-H3. Robust supply chain, strategic partnerships, and a strong team support rapid clinical advancement and broad market potential.